Previous Article
Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras
Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras

LMNL today announced that the first subject has been dosed in the Company’s fezagepras Phase 1 multiple asc...

Next Flipbook
Quarterly Report Q3 2020
Quarterly Report Q3 2020

Go to Liminal BioSciences Q4 and Year-End Results Conference Call on Thursday March 25, 2021 8:30 AM EST

View Now